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Abstract Rheumatoid arthritis (RA) is a chronic auto-
immune di sease pr imar i ly ta rge t ing the jo in t s .
Approximately 1% of the population is affected by RA, and
despite the improvements in therapeutic interventions, eluci-
dation of the disease pathogenesis is still in its infancy. RA
patients can be subdivided on basis of the presence of autoan-
tibodies, especially anti-citrullinated protein antibodies
(ACPA). ACPA+ and ACPA− disease most likely differ in
aetiology, as different genetic and environmental risk factors
are associated with these two disease entities. For ACPA+ RA
disease, the genetic factors associating with disease mainly
comprised of human leukocyte antigen (HLA) class II mole-
cules. The predisposing HLA-DR alleles have been depicted
as the ‘HLA Shared Epitope (SE) alleles’, as these alleles
encode a similar sequence, the shared epitope sequence, with-
in the beta chain of the HLA-DR molecule. In addition to the
involvement of the HLA-SE alleles in the development of
ACPA+ RA disease, other HLA-DR molecules have been
shown to confer protection against this disease entity. The
protective HLA molecules have, instead of the SE-motif, a
different but shared sequence at the same location in the beta
chain of HLA-DR molecules, consisting of the amino acid
residues DERAA. The possible contributions of the
predisposing and protective HLA molecules in association
with ACPA-positive RA are discussed in this review.
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Introduction
Rheumatoid arthritis (RA) is a chronic auto-inflammatory dis-
ease that primarily affects the joints. Worldwide the preva-
lence ranges between 0.5 and 1% with a few populational
exceptions and a higher occurrence in females than in males
(Silman& Pearson, 2002). One of the first humoral markers to
be identified within the RA patient population has been the
presence of rheumatoid factor (RF), an antibody that targets
the Fc region of immunoglobulin G (IgG) molecules (Zvaifler,
1973). However, this specific antibody is also present in a
variety of other diseases. Another antibody response with
higher specificity for RA was shown to target citrullinated
proteins. Citrullination is a posttranslational modification
converting peptidylarginine residues into peptidylcitrulline in-
volving the peptidylarginine deiminase (PAD) enzyme. A
consequence of this modification is the reduction of the net-
positive charge of the protein. Not all RA patients produce
these antibodies, making a distinction between the RA popu-
lations that do- or do not harbour Anti-citrullinated protein
antibodies (ACPA). ACPA positivity has been shown to be a
predictive marker for the development of RA in patients with
joint complaints (van Gaalen et al., 2004) and patients
harbouring ACPAs experience a more aggressive disease pro-
gression than patients without ACPA (van der Helm-van Mil,
Verpoort, Breedveld, Toes, & Huizinga, 2005). This distinc-
tion between these two disease entities was further empha-
sized by differences in underlying genetic risk factors and
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environmental risk factors, pointing towards a different
aetiology and pathophysiology between ACPA+ and ACPA
− RA disease.
HLA associations with RA
In several twin studies, the heritability of RAwas estimated to
be approximately 60%, pointing towards a substantial influ-
ence of genetic risk factors on the development of RA disease
(MacGregor et al., 2000). Recent genome-wide association
studies (GWAS) have identified 101 single nucleotide poly-
morphism (SNPs) in total, showing the highest contribution of
the hla-drb1 gene to the development of RA (Eyre et al., 2012;
Okada et al., 2012; Okada et al., 2014b; Stahl et al. 2010).
Hla-drb1-encoded proteins are components of human leuko-
cyte antigen-DR (HLA-DR) molecules and together with
HLA-DQ and HLA-DP, they represent the major determinants
in the induction of adaptive immune responses. They are
expressed, amongst others, by antigen-presenting cells
(APCs) and are able to present peptides to CD4+ T cells. In
the 1970s, HLA-Dw4 was shown to be present in the majority
of the RA patients (Stastny 1976) which was confirmed by
serological HLA-typing identifying HLA-DR4 and HLA-
DR1 in association with RA. Nowadays, the list of HLA al-
leles conferring increased risk for RA development is largely
known (listed in Table 1) albeit with altered nomenclature.
The predisposing HLA-DR alleles were found to have a par-
ticular sequence in common, located in the beta chain (HLA-
DRB1) at positions 70–74 (Gregersen et al. 1987). This has
later become known as the shared epitope sequence and as
such, the HLA-DR alleles carrying this particular sequence
were designated as ‘Shared Epitope alleles’(SE-alleles). In
2005, it was discovered that the genetic contribution of the
HLA locus did not apply to RA as such, but rather to ACPA-
positive RA only (Huizinga et al. 2005). These data are im-
portant as they indicate that ACPA-positive and ACPA-
negative RA represent different disease entities with a differ-
ent underlying pathophysiology. More recently, positions 11
and 13 (Table 1), which are also part of the peptide-binding
groove, have been implicated in the association between HLA
and RA (Raychaudhuri et al. 2012). However, as these posi-
tions are the most polymorphic in the HLA-region, these two
positions most likely represent the best proxy for the predis-
posing HLA molecules explaining their association with RA
in statistical terms.
Shared epitope alleles and RA
Epidemiology
The contribution of HLA alleles to RA development has
been extensively studied by means of meta-analyses in
different populations, including the Asians, Caucasians
and native Americans. These studies show that especial-
ly the HLA-SE alleles increase the risk of developing
RA in every population, although there are discrepan-
cies in the degree of contribution of each allele when
comparing populations (Okada et al. 2014a; van der
Woude et al. 2010a; Willkens et al. 1991). The presence
of combined SE-alleles within individuals increases the
risk of developing ACPA+ RA even more (Mackie et al.
2012). Interestingly, even though the SE-alleles confer
the highest risk, some non-SE alleles have also been
identif ied as predisposing. For example, HLA-
DRB1*09:01 is not considered a shared epitope allele
by a small difference in the five residues located at
positions 70–74 (Bondinas et al. 2007); however, in
meta-analyses, the presence of HLA-DRB1*09:01 has
shown an increase in odds ratio (van der Woude et al.
2010a; Willkens et al. 1991). This notion indicates that
the involvement of HLA class II molecules may be
dependent on more than just the shared epitope
sequence.
Citrulline presentation by shared epitope alleles
HLA class II molecules consist of 2 protein chains, the
alpha and beta chain (Fig. 1a), both encoded by different
genes. The combination of the two chains together forms
a molecule with a peptide-binding groove for the presen-
tation of peptides (Fig. 1a). This peptide-binding groove
consists of 4–5 peptide-binding pockets, accommodating
different residues of the bound peptide ligand (Fig. 1b).
The amino acids involved in the formation of these
pockets are key determinants in restricting the peptide
repertoire that can be accommodated. Even though pep-
tides of variable lengths can bind to HLA class II mole-
cules, the core sequence of these peptides consists of 9
amino acids. Of these 9 amino acids, 4–5 residues will get
enclosed by the HLA molecule, in peptide-binding
pockets 1, 4, 6, (7) and 9, whereas the remainder is avail-
able for T cell receptor (TCR) recognition (Fig. 1b).
The previously mentioned shared epitope sequence
e i t h e r cons i s t s o f t h e r e s i due s 7 0QKRAA74 ,
70QRRAA74 or 70RRRAA74. Three (residue 70, 71 and
74) out of the five amino acids are involved in the
shaping of peptide-binding pocket 4 of the HLA mole-
cule. The presence of one or two positively charged
re s idues ( l y s ine , K ; a rg in ine , R ) wi th in the
pocket alters the permissiveness of the binding of
positively-charged residues at that position, enabling en-
hanced binding capacity of citrullinated peptides com-
pared to the native peptide (Fig. 1c). To confirm this
enhanced binding capacity, Hill et al. performed
peptide-binding assays showing that the HLA-SE mole-
cules were capable of binding citrullinated peptides with
598 Immunogenetics (2017) 69:597–603
higher affinity than their native counterparts (Hill et al.
2003). Indeed, subsequent HLA-DRB1*04:01-peptide
crystal structures clearly showed that this HLA-
molecule exhibited an enhanced ability to accommodate
citrulline, but not arginine, within peptide-binding pock-
et 4 (Scally et al. 2013). However, recent evidence in-
dicates that not only the Shared Epitope motif within
peptide-binding pocket 4 contributes to citrulline bind-
ing, as pockets 7 and 9 are also capable of accommo-
dating citrulline more efficiently. In addition, we have
shown that HLA-DQ molecules, that are in tight
linkage-disequilibrium (LD) with predisposing HLA-DR
molecules (HLA-DQ8 and –DQ7, in LD with HLA-
DR4), but also ‘neutral’ HLA-DQ molecules (HLA-
DQ2, in LD with HLA-DR3), are able to accommodate
citrullinated peptides better as their non-modified coun-
terparts. Moreover, they can do so in multiple pockets
(Kampstra et al. 2016). Therefore, the association be-
tween SE-alleles and the development of ACPA+ RA
disease may not be explained fully by enhanced binding
of citrullinated peptides by these alleles as the interac-
tions between citrullinated peptides and HLA molecules
seem to be more complex. In addition, due to the tight
LD between HLA-DR and –DQ molecules, it is compli-
cated to define the precise contribution of these mole-
cules to RA pathogenesis.
T cell recognition of citrullinated peptides
In contrast to the increasing data on the ACPA response, in-
cluding the ACPA-expressing B cell response, knowledge on
the nature of the T cells involved in RA is limited. As men-
tioned previously, the HLA class II molecules present peptides
to activate and/or modulate the CD4+ T cell response. T cells
can exert a diversity of functions including the promotion of
the immune response by helping B cells. Recent studies have
shown that the HLA class II locus is associated with
established ACPA+ disease, but, surprisingly, only to a limited
extend with ACPA-positivity in healthy subjects. Therefore, it
is likely that the CD4+ T helper cells restricted by the
Table 1 Association of HLA-DRB1 alleles with ACPA+ RA disease. Depicted are the residues located at various positions for a diversity of HLA-
DRB1 alleles. Not all known HLA alleles are shown here. The presence of the SE-sequence is indicated with a tick, as well as the association with
predisposition or protection against ACPA+ RA disease for each allele
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predisposing HLA molecules play a role in the development
of ACPA+ disease rather than in the development of ACPA
positivity. The contribution of this T cell-help may lie in the
facilitation of the maturation of the antibody response by B
cells, as relatively short before the onset of symptoms, the
antibody response has been shown to expand in level, isotype
usage and fine specificity recognition profile (Suwannalai
et al. 2012; van de Stadt et al. 2011; van der Woude et al.
2010b; Verpoort et al. 2006). Despite the increasing knowl-
edge on the nature of citrullinated antigens recognized by
ACPAs, knowledge on T cell receptor specificity is still
scarce. Next-generation sequencing has shown that there
might be oligoclonal expansion of T cell populations; never-
theless, common TCR specificities were not identified among
different RA patients (Klarenbeek et al. 2012). The difficulty
in identifying the T cell reaction involved in RA pathogenesis
might be partially due to the cross-reactive nature of ACPA,
being able to recognize many citrullinated proteins. Therefore,
the antigens recognized by B cells in vitro are not necessarily
the same antigens that are recognized by T cells in vivo, mak-
ing it challenging to pinpoint a specific dominant T cell re-
sponse in RA patients. Moreover, because of the cross-
reactive nature of ACPA, it is conceivable that the auto-
reactive ACPA-expressing B cells also react to citrullinated
proteins from microbes, thereby allowing the recruitment of
microbe-directed Tcells, instead of auto-reactive Tcells, in the
help provided to ACPA-producing B cells. Therefore, it has
yet to be elucidated whether and to what extent T cells are
auto-reactive in nature. Despite these challenges, studies have
shown the existence of T cells specific for citrullinated pep-
tides in mice. For example, HLA-DR4 (HLA-DRB1*04:01)
transgenic mice immunized with 2 naturally processed pep-
tides derived from citrullinated vimentin, readily respond to
these with the production of interferon-gamma. This response
was both restricted to the citrullinated form of the peptide and
to the presentation of the peptide in the context of HLA-DR
(Feitsma et al. 2010; James et al. 2014). In addition, multiple
studies suggest that such citrullinated peptide-specific T cells
can also be present in RA patients, although they are also
found in healthy controls (Hill et al. 2003; James et al. 2014;
Scally et al. 2013).
HLA-DR13 and RA
Epidemiology
Since the identification of the HLA-SE alleles, the majority of
studies have focused on the association between the presence
of HLA-SE alleles and RA. Another facet of the HLA associ-
ation with ACPA+ RA is found in the presence of protective
HLA alleles. These protective HLA alleles have been catego-
rized according to three classifications: the presence of the
sequence ‘DERAA’ at positions 70–74 of the beta chain, the
presence of an aspartic acid at position 70 or the presence of an
isoleucine at position 67 (Table 1). An extensive meta-
analysis on the influence of multiple HLA alleles has shown
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Fig. 1 Schematic representation of a peptide binding to a HLA-DR
molecule. a Top view of the peptide binding groove. The peptide
binding groove is formed by the alpha and beta chain, leaving, forming
two walls to accommodate the peptide. b Side-view of the peptide-
binding groove without distinguishment between the two HLA-DR
chains. The peptide-binding pockets shown are anchoring points for
residues of the peptide. The other residues are available for T cell
receptor recognition. c Representation of how the shared epitope
sequence can influence the binding of residues. Due to the presence of
positively charged residues within pocket 4, arginine may be repelled and
citrulline may be accepted. X represents any amino acid involved in
formation of pocket 4. Position of residues within peptide-binding
pocket 4 does not represent the actual position. d Representation of
how the DERAA-sequence can influence the binding of residues. Due
to the presence of negatively charged residues within pocket 4, both
arginine and citrulline may be accepted. X represents any amino acid
involved in formation of pocket 4. Position of residues within peptide-
binding pocket 4 does not represent the actual position
600 Immunogenetics (2017) 69:597–603
lesser extent HLA-DRB1*13:02, confers protection in
ACPA+ RA but not ACPA− RA in four different populations
(Salvat et al. 1994; van der Woude et al. 2010a). In line with
these observations, a different study has shown that HLA-
DRB1*13 confers protection against ACPA+ RA rather than
ACPA positivity (van Heemst et al. 2016). The mechanism
how HLA molecules can protect against ACPA+ disease de-
velopment is yet to be elucidated; nevertheless, several ideas
have been postulated.
Citrulline presentation by protective HLA molecules
Despite the in-depth analyses of the association between
HLA-DRB1*13 and ACPA+ RA disease, only limited data
are available on the ability of HLA-DRB1*13, or other
protection-associated HLA molecules, to bind citrullinated
or native peptides. Nonetheless, in contrast to the predisposing
HLA molecules, the HLA molecules associated with protec-
tion seem to be able to accommodate both citrullinated- and
native peptides with similar efficiency as reported using a
model peptide from vimentin (Hill et al. 2003; Scally et al.
2013) (Fig. 1d). Therefore, it was proposed that due to the
increased binding affinity of citrulline for the predisposing
HLA molecules, the number of peptide-HLA complexes is
increased on the cell surface as opposed to the neutral or
protective peptide-HLA complexes (Hill et al. 2003). As the
level of peptides presented by protective HLA molecules is
less likely to reach the threshold for T cell activation, the so-
called ‘biochemical margin of safety’ (Hill et al. 2003;
Peterson et al. 1999), it will not lead to T cell activation or
might even lead to induction of regulatory Tcells (Jordan et al.
2001; Peterson et al. 1999). In addition, peptides that bind
with higher affinity to HLA molecules increase the lifespan
of the peptide-HLA complex on the cell surface, increasing
the opportunity of T cells to recognize the presented peptide
(Nelson et al. 1994). However, whether these features are
related to the immunogenetic data remains a question that is
yet to be elucidated.
HLA-DERAA presentation by thymic APCs
HLA molecules can present an array of peptides derived from
endogenous proteins whereby the peptides presented by HLA
class II molecules are often derived from proteins from the cell
membrane (Rammensee and Friede, 1995). Therefore, it is no
surprise that HLA class II molecules also present peptide de-
rived from other HLA proteins (Chicz et al. 1992). Given the
protective effects associated with some HLAmolecules, it has
been proposed that the presentation of a specific epitope de-
rived from HLA molecules protect against development of
arthritis through the induction of regulatory T cells recogniz-
ing such peptides. For example, it was proposed that the mu-
rine MHC molecule H-2Ebd is able to confer protection
through the presentation of a peptide derived from its high
variable domain 3 (HV3) by H-2Aq (Zanelli et al. 1995). In
this case, it was hypothesised that protection would be medi-
ated through the induction of anergic, regulatory T cells.
Because presentation of peptides derived from MHC class II
molecules by other MHC class II molecules could potentially
lead to the formation of regulatory T cell responses, it was
proposed that Tcells specific for the HV3 region are positively
selected in the thymus and subsequently could contribute to
immune regulation and inhibition of auto-immunity in mice
and men (Zanelli et al. 1995). Indeed, it has been shown that a
peptide derived from the protective HLA-DRB1*04:02, but
not from HLA-DRB1*0401, can be presented by HLA-DQ8
and be recognized by HLA-DQ8-restricted T cells, supporting
the notion that peptides from the HV3 region of HLA mole-
cules can serve as T cell targets (Snijders et al. 2001).
HLA-DR13 and RA: how could they connect?
A possible biological explanation of the protective effects
associated with HLA-DR13 was found in the presence of
the sequence 70DERAA74 encoded by HLA-DR13 and
other protective HLA molecules (van Heemst et al.
2015). Next to several HLA alleles associated with pro-
tection against ACPA+ RA, the DERAA-sequence can al-
so be found in a few other human self-proteins including
vinculin (VCL). Vinculin is a component of the cytoskel-
eton, ubiquitously expressed in all cell lineages. It has
been shown to be citrullinated within the inflamed joints
of RA patients (van Beers et al. 2013), and to be recog-
nized by ACPA in its citrullinated form (van Heemst et al.
2015). Moreover, T cell tolerance against vinculin had
previously been reported not to be absolute (Propato
et al. 2001) as under certain pathological conditions the
presence of T cells recognizing vinculin have been report-
ed. Interestingly, comparing HLA-DRB1*13:01-positive
and HLA-DRB1*13:01-negative individuals revealed that
T cell reactivity against ‘vinculin-DERAA’ was readily
detectable in many HLA-DR13-negative individuals, but
absent in HLA-DR13-positive subjects. Moreover, when
binding affinity of the ‘VCL-DERAA’ peptide to different
HLA molecules was examined, it was shown that the pep-
tide was able to bind to all HLA-DQ molecules that are
associated with ACPA-positive RA (i.e. HLA-DQ7, -DQ8
and -DQ5) as these molecules are in strong linkage dis-
equilibrium with predisposing HLA-DR molecules. In
contrast, the HLA molecules analysed that do not associ-
ate with arthritis, did not bind this peptide, suggesting a
link between the ability to present this peptide and the
predisposition to ACPA+ RA. Interestingly, it was subse-
quently shown that a T clone against the ‘VCL-DERAA’
peptide also cross-reacted to several ‘DERAA’-containing
epitopes present in microbes. These peptides bound the
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predisposing HLA-DQ molecules as well and were recog-
nized by a substantial number of HLA-DR4-DQ8/7.3-pos-
itive donors. However, such T cells remained undetectable
in donors additionally expressing the protective HLA-
DR13 molecule. Therefore, a possible mechanism
explaining the presence of ‘VCL-DERAA’-specific T cells
is found in the notion that a breach of tolerance is induced
following exposure to a microbe-harbouring protein that
resembles the VCL-DERAA sequence. This could lead to
the induction of cross-reactive T cells that recognize the
auto-antigen vinculin. Intriguingly, the DERAA-sequence
is present in 66% of bacteria and 4% of viruses, indicating
that everyone will be exposed to such microbes. Thus,
taking both the ability of a VCL-DERAA-directed T cells
to respond to ‘DERAA’-containing epitopes from mi-
crobes, and the apparent selective absence of reactivity
of such T cells within HLA-DR13+ individuals, an hy-
pothesis describing the connection between HLA and
RA has been proposed. In short, upon encounter and pe-
ripheral priming by microbial-derived DERAA-containing
peptides, ‘DERAA’-directed T cells will be activated in
individuals expressing HLA molecules that can present
such peptides (i.e. the HLA-DQ molecules predisposing
to RA). Some of these T cells show cross-reactivity with
VCL-DERAA and thereby allow the provision of help to
ACPA-expressing B cells that recognize citrullinated vin-
culin (a target of ACPA that is also present in citrullinated
form in the inflamed joint). In contrast, individuals carry-
ing the protective HLA molecules will not be able to
mount such T cell responses as these T cells are
hypothesised to be negatively selected in the thymus by
presentation of the DERAA-sequence derived from pro-
tective HLA molecules. Therefore, by virtue of the ab-
sence of such T cells, ACPA-expressing B cells recogniz-
ing citrullinated vinculin will not receive T cell-help
explaining the protective effects of HLA-DR13 to
ACPA-positive RA (van Heemst et al. 2015).
Concluding remarks
The association between the HLA-system and RA has been
studied intensively in the past 40 years thereby addressing
many aspects involved in the pathogenesis of RA. Even
though many breakthroughs have been made, there is yet so
much more to be elucidated, primarily within the context of
which role Tcells play during the development of ACPA+ RA.
The elucidation of the exact events underlying the develop-
ment of ACPA+ RA might provide relevant insights into the
role of T cells and peptide presentation by HLA class II mol-
ecules and thereby the pathogenesis of this frequent auto-
immune disease. It is likely that many aspects on the role of
Tcells in ACPA+ disease will be clarified in the years to come,
most likely unveiling several pathways the T cells employ to
contribute to the arousal of ACPA+ RA.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Bondinas GP, Moustakas AK, Papadopoulos GK (2007) The spectrum of
HLA-DQ and HLA-DR alleles, 2006: a listing correlating sequence
and structure with function. Immunogenetics 59:539–553. doi:10.
1007/s00251-007-0224-8
Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA,
Strominger JL (1992) Predominant naturally processed peptides
bound to HLA-DR1 are derived from MHC-related molecules and
are heterogeneous in size. Nature 358:764–768. doi:10.1038/
358764a0
Eyre S et al (2012) High-density genetic mapping identifies new suscep-
tibility loci for rheumatoid arthritis. Nat Genet 44:1336–1340. doi:
10.1038/ng.2462
Feitsma AL et al (2010) Identification of citrullinated vimentin peptides
as T cell epitopes in HLA-DR4-positive patients with rheumatoid
arthritis. Arthritis Rheum 62:117–125. doi:10.1002/art.25059
Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hy-
pothesis. An approach to understanding the molecular genetics of
susceptibility to rheumatoid arthritis Arthritis Rheum 30:1205–1213
Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E (2003)
Cutting edge: the conversion of arginine to citrulline allows for a
high-affinity peptide interaction with the rheumatoid arthritis-
associated HLA-DRB1*0401 MHC class II molecule. J Immunol
171:538–541
Huizinga TW et al (2005) Refining the complex rheumatoid arthritis
phenotype based on specificity of the HLA-DRB1 shared epitope
for antibodies to citrullinated proteins. Arthritis Rheum 52:3433–
3438. doi:10.1002/art.21385
James EA et al (2014) Citrulline-specific Th1 cells are increased in rheu-
matoid arthritis and their frequency is influenced by disease duration
and therapy. Arthritis Rheumatol 66:1712–1722. doi:10.1002/art.
38637
Jordan MS et al (2001) Thymic selection of CD4+CD25+ regulatory T
cells induced by an agonist self-peptide. Nat Immunol 2:301–306.
doi:10.1038/86302
Kampstra AS, van Heemst J, Moustakas AK, Papadopoulos GK,
Huizinga TW, Toes RE (2016) The increased ability to present
citrullinated peptides is not unique to HLA-SE molecules:
arginine-to-citrulline conversion also enhances peptide affinity for
HLA-DQ molecules. Arthritis Res Ther 18:254. doi:10.1186/
s13075-016-1153-4
Klarenbeek PL et al (2012) Inflamed target tissue provides a specific
niche for highly expanded T-cell clones in early human autoimmune
disease. Ann Rheum Dis:71, 1088–1093. doi:10.1136/
annrheumdis-2011-200612
MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K,
Silman AJ (2000) Characterizing the quantitative genetic contribu-
tion to rheumatoid arthritis using data from twins. Arthritis Rheum
43:30–37. doi:10.1002/1529-0131(200001)43:1<30::AID-
ANR5>3.0.CO;2-B
602 Immunogenetics (2017) 69:597–603
Mackie SL et al (2012) A spectrum of susceptibility to rheumatoid arthri-
tis within HLA-DRB1: stratification by autoantibody status in a
large UK population. Genes Immun 13:120–128. doi:10.1038/
gene.2011.60
Nelson CA, Petzold SJ, Unanue ER (1994) Peptides determine the
lifespan of MHC class II molecules in the antigen-presenting cell.
Nature 371:250–252. doi:10.1038/371250a0
Okada Y et al (2014a) Risk for ACPA-positive rheumatoid arthritis is
driven by shared HLA amino acid polymorphisms in Asian and
European populations. Hum Mol Genet 23:6916–6926. doi:10.
1093/hmg/ddu387
Okada Y et al (2012) Meta-analysis identifies nine new loci associated
with rheumatoid arthritis in the Japanese population. Nat Genet 44:
511–516. doi:10.1038/ng.2231
Okada Y et al (2014b) Genetics of rheumatoid arthritis contributes to
biology and drug discovery. Nature 506:376–381. doi:10.1038/
nature12873
Peterson DA, DiPaolo RJ, Kanagawa O, Unanue ER (1999) Cutting
edge: negative selection of immature thymocytes by a few
peptide-MHC complexes: differential sensitivity of immature and
mature T cells. J Immunol 162:3117–3120
Propato A et al (2001) Apoptotic cells overexpress vinculin and induce
vinculin-specific cytotoxic T-cell cross-priming. Nat Med 7:807–
813. doi:10.1038/89930
Rammensee HG, Friede T, Stevanoviic S (1995) MHC ligands and pep-
tide motifs: first listing. Immunogenetics 41:178–228
Raychaudhuri S et al (2012) Five amino acids in three HLA proteins
explain most of the association between MHC and seropositive
rheumatoid arthritis. Nat Genet 44:291–296. doi:10.1038/ng.1076
Salvat S, Auger I, Rochelle L, Begovich A, Geburher L, Sette A, Roudier
J (1994) Tolerance to a self-peptide from the third hypervariable
region of HLA DRB1*0401 in rheumatoid arthritis patients and
normal subjects. J Immunol 153:5321–5329
Scally SWet al (2013) A molecular basis for the association of the HLA-
DRB1 locus, citrullination, and rheumatoid arthritis. J ExpMed 210:
2569–2582. doi:10.1084/jem.20131241
Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid
arthritis. Arthritis Res 4(Suppl 3):S265–S272. doi:10.1186/ar578
Snijders A et al (2001) An HLA-DRB1-derived peptide associated with
protection against rheumatoid arthritis is naturally processed by hu-
man APCs. J Immunol 166:4987–4993
Stahl EA et al (2010) Genome-wide association study meta-analysis iden-
tifies seven new rheumatoid arthritis risk loci. Nat Genet 42:508–
514. doi:10.1038/ng.582
Stastny P (1976) Mixed lymphocyte cultures in rheumatoid arthritis. J
Clin Invest 57:1148–1157. doi:10.1172/JCI108382
Suwannalai P et al (2012) Avidity maturation of anti-citrullinated protein
antibodies in rheumatoid arthritis. Arthritis Rheum 64:1323–1328.
doi:10.1002/art.33489
van Beers JJ, Schwarte CM, Stammen-Vogelzangs J, Oosterink E, Bozic
B, Pruijn GJ (2013) The rheumatoid arthritis synovial fluid
citrullinome reveals novel citrullinated epitopes in apolipoprotein
E, myeloid nuclear differentiation antigen, and beta-actin. Arthritis
Rheum 65:69–80. doi:10.1002/art.37720
van de Stadt LA, de Koning MH, van de Stadt RJ, Wolbink G, Dijkmans
BA, Hamann D, van Schaardenburg D (2011) Development of the
anti-citrullinated protein antibody repertoire prior to the onset of
rheumatoid arthritis. Arthritis Rheum 63:3226–3233. doi:10.1002/
art.30537
van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE,
Huizinga TW (2005) Antibodies to citrullinated proteins and differ-
ences in clinical progression of rheumatoid arthritis. Arthritis Res
Ther 7:R949–R958. doi:10.1186/ar1767
van derWoudeD et al (2010a) Protection against anti-citrullinated protein
antibody-positive rheumatoid arthritis is predominantly associated
with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associa-
tions with anti-citrullinated protein antibody-positive and anti-
citrullinated protein antibody-negative rheumatoid arthritis in four
European populations. Arthritis Rheum 62:1236–1245. doi:10.
1002/art.27366
van der Woude D et al (2010b) Epitope spreading of the anti-citrullinated
protein antibody response occurs before disease onset and is associ-
ated with the disease course of early arthritis. Ann Rheum Dis 69:
1554–1561. doi:10.1136/ard.2009.124537
van Gaalen FA et al (2004) Autoantibodies to cyclic citrullinated peptides
predict progression to rheumatoid arthritis in patients with undiffer-
entiated arthritis: a prospective cohort study. Arthritis Rheum 50:
709–715. doi:10.1002/art.20044
van Heemst J et al (2016) Protective effect of HLA-DRB1*13 alleles
during specific phases in the development of ACPA-positive RA.
Ann Rheum Dis 75:1891–1898. doi:10.1136/annrheumdis-2015-
207802
van Heemst J et al (2015) Crossreactivity to vinculin and microbes pro-
vides a molecular basis for HLA-based protection against rheuma-
toid arthritis. Nat Commun 6:6681. doi:10.1038/ncomms7681
Verpoort KN et al (2006) Isotype distribution of anti-cyclic citrullinated
peptide antibodies in undifferentiated arthritis and rheumatoid arthri-
tis reflects an ongoing immune response. Arthritis Rheum 54:3799–
3808. doi:10.1002/art.22279
Willkens RF, Nepom GT, Marks CR, Nettles JW, Nepom BS (1991)
Association of HLA-Dw16 with rheumatoid arthritis in Yakima
Indians. Further evidence for the "shared epitope" hypothesis.
Arthritis Rheum 34:43–47
Zanelli E, Gonzalez-Gay MA, David CS (1995) Could HLA-DRB1 be
the protective locus in rheumatoid arthritis? Immunol Today 16:
274–278. doi:10.1016/0167-5699(95)80181-2
Zvaifler NJ (1973) The immunopathology of joint inflammation in rheu-
matoid arthritis. Adv Immunol 16:265–336
Immunogenetics (2017) 69:597–603 603
